癌变·畸变·突变 ›› 2018, Vol. 30 ›› Issue (3): 194-199.doi: 10.3969/j.issn.1004-616x.2018.03.006

• 论著 • 上一篇    下一篇

肉苁蓉苯乙醇总苷抗肝癌作用的实验研究

胡琼1, 由淑萍2, 刘涛1, 汪波1, 刘昕1, 蒋远东1   

  1. 1. 新疆医科大学公共卫生学院, 新疆 乌鲁木齐 830011;
    2. 新疆医科大学护理学院, 新疆 乌鲁木齐 830011
  • 收稿日期:2018-03-01 修回日期:2018-03-09 出版日期:2018-05-30 发布日期:2018-05-30
  • 通讯作者: 刘涛,E-mail:xjmult@163.com E-mail:xjmult@163.com
  • 作者简介:胡琼,E-mail:1076609166@qq.com。
  • 基金资助:
    国家级大学生创新计划项目(201610760013);新疆医科大学大学生创新计划项目(CX2016013)

An investigation on the anti-liver cancer effect of cistanche

HU Qiong1, YOU Shuping2, LIU Tao1, WANG Bo1, LIU Xin1, JIANG Yuandong1   

  1. 1. College of Public Health, Xinjiang Medical University, Urumqi 830011;
    2. School of Nursing, Xinjiang Medical University, Urumqi 830011, Xinjiang, China
  • Received:2018-03-01 Revised:2018-03-09 Online:2018-05-30 Published:2018-05-30

摘要: 目的:研究肉苁蓉苯乙醇总苷(CPhGs)的抗肝癌作用,并探讨其可能的作用机制。方法:采用前肢右侧腋部皮下注射法建立小鼠肝癌H22荷瘤模型,实验设空白对照组、肝癌H22荷瘤模型组、肝复乐阳性治疗组(1 351.5 mg/kg)、CPhGs高剂量组(500 mg/kg)、中剂量组(250 mg/kg)、低剂量组(125 mg/kg),共6组,每组10只。除空白对照组和模型组外,其余各组分别灌胃给予肝复乐或CPhGs,连续10 d。期间监测小鼠的一般状况,观察各组H22荷瘤小鼠瘤体生长情况,实验结束时,摘眼球取血,酶联免疫(ELISA)法检测血清白介素2(IL-2)、肿瘤坏死因子α(TNF-α)和甲胎蛋白(AFP)含量;分离脾脏、肝脏,称质量,计算脏器系数;完整剥取瘤体,计算各组小鼠的肿瘤抑制率;HE染色观察瘤体病理组织学变化。结果:荷瘤模型组动物腋下肿瘤出现早且生长最快,CPhGs低、中剂量组次之,高剂量组和阳性治疗组瘤体生长较慢。与模型组比较,CPhGs中、高剂量组瘤质量均明显降低(P < 0.05),各剂量组抑癌率随CPhGs剂量增加依次升高(P < 0.05);阳性治疗组和CPhGs各剂量组脾脏系数均明显升高及肝脏系数均明显降低(P < 0.05);CPhGs中、高剂量组和阳性治疗组IL-2含量均明显升高(P < 0.05),而AFP含量均明显降低(P < 0.05);CPhGs各剂量组和阳性治疗组TNF-α含量均明显降低(P < 0.05)。病理结果发现CPhGs各剂量组小鼠肝癌细胞生长受到抑制、数目较少、异质性降低、并伴有大量坏死细胞。结论:CPhGs能降低肝癌H22荷瘤小鼠肝脏损伤,并对其肿瘤生长有抑制作用,可能与CPhGs降低荷瘤小鼠血清中AFP含量及提高荷瘤小鼠免疫能力有关。

关键词: 肉苁蓉, 苯乙醇总苷, H22细胞, 肝癌

Abstract: OBJECTIVE: To study the anti-liver cancer effect of phenylethanol glycosides from cistanche (CPhGs) in mice. METHODS: H22 tumor-bearing mice were established by using axillary subcutaneous injections. Six groups of 10 mice were used in our study:the experiment established blank control group,H22 tumor-bearing model group,Ganfule positive treatment group (1 351.5 mg/kg),and CPhGs high,medium and low dose groups (500,250,125 mg/kg). In addition to the blank control and the model groups,the rest of them were given Ganfule or CPhGs by gavage for 10 consecutive days. During the period,conditions of these mice were monitored,and the tumor growth of H22 tumor-bearing mice was observed. At the end of the experiment,blood was collected from the eyeball,and serum interleukin-2 (IL-2),tumor necrosis factor-α (TNF-α) and α-fetoprotein (AFP) content were detected by enzyme linked immunosorbent assay (ELISA). Biological samples were collected to calculate the spleen,liver coefficient and inhibition rate. HE staining was conducted to observe pathological histologic changes. RESULTS: The axillary tumor in the model group grew early and grew the fastest,followed by the CPhGs low and medium dose groups. The tumor growth of the high dose group and the positive treatment group were slower. Compared with the model group,the quality of tumor in the CPhGs medium and high dose groups was significantly reduced,and the inhibition rate of each dose group was increased with increasing doses of CPhGs (P < 0.05). The spleen coefficient of the positive treatment group and each CPhGs dose group were significantly increased,and liver coefficient were obviously decreased (P < 0.05). Among the high dose and positive treatment groups,IL-2 contents were significantly elevated (P < 0.05). Each CPhGs dose group and positive treatment group,TNF-α contents were significantly reduced (P < 0.05). Among CPhGs medium,high dose and positive treatment groups,AFP content were significantly reduced (P < 0.05). Pathological results show that the tumor cells in each CPhGs dose group were suppressed with reduced numbers,the heterogeneity was reduced,and there were large numbers of necrotic cells. CONCLUSION: CPhGs exposure reduced liver injury of H22 tumor-bearing mice,adversely affected tumor growth which was probably related to reduce AFP levels in serum of tumor-bearing mice,and improved immune function of tumor-bearing mice.

Key words: cistanche, phenylethanol glycosides from cistanche, H22 cells, liver cancer

中图分类号: